公开(公告)号：EP3402521A1

公开(公告)日：2018-11-21

申请号：EP17739165.3

申请日：2017-01-17

申请人： AnaptysBio, Inc.

发明人： LONDEI, Marco

IPC分类号： A61K39/395 ,  A61P37/08 ,  C07K16/24 ,  C12N15/13

CPC分类号： A61K39/395 ,  C07K16/244 ,  C07K2317/76

摘要： A method of inhibiting or preventing an allergic reaction, particularly to a food antigen, in a mammal comprising administering to the mammal an IL-33 inhibitor.

公开(公告)号：EP3277321A1

公开(公告)日：2018-02-07

申请号：EP16774301.2

申请日：2016-04-01

申请人： AnaptysBio, Inc.

发明人： KEHRY, Marilyn ,  KING, David J. ,  DA SILVA CORREIA, Jean

IPC分类号： A61K39/395 ,  C07K16/28

CPC分类号： C07K16/2809 ,  A61K2039/507 ,  A61P35/00 ,  A61P37/00 ,  C07K16/2803 ,  C07K16/2815 ,  C07K16/2818 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  Y02A50/386

摘要： The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the T Cell Immunoglobulin and Mucin Protein-3 (HM-3). The invention provides a TIM-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the TIM-3-binding agent to treat a disorder or disease that is responsive to TIM-3 inhibition, such as cancer, an infectious disease, or an autoimmune disease.

公开(公告)号：EP1576154B8

公开(公告)日：2011-04-13

申请号：EP03779576.2

申请日：2003-12-18

申请人： AnaptysBio, Inc.

发明人： IRVING, Robert, Alexander ,  HUDSON, Peter, John ,  MUSTAFA, Huseyin ,  WARK, Kim ,  ABREGU, Matias, Ezequiel

IPC分类号： C12N15/10 ,  C12N15/63

CPC分类号： C40B40/02 ,  C12N15/102 ,  C12N15/1037

摘要： The present invention relates to the field of evolution of nucleic acids in vivo and provides methods and compositions for introducing diversity into gene products. The present invention allows generation of new sequences that have desirable properties by virtue of high frequency mutation events within a cell. The high frequency mutation of a polynucleotide sequence results in the production of a large population of new sequence variants. Appropriate selection and/or screening permits identification and isolation of mutant forms of the polynucleotide sequence as well as products resulting from expression of the mutant sequences.

公开(公告)号：EP2126105A4

公开(公告)日：2010-11-03

申请号：EP08725985

申请日：2008-02-20

申请人： ANAPTYSBIO INC

发明人： HORLICK ROBERT A ,  CUBITT ANDREW B ,  BOWERS PETER M

IPC分类号： C12P19/34 ,  C12N15/11 ,  C12N15/85

CPC分类号： C07K16/461 ,  C07K16/00 ,  C07K16/22 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/92 ,  C40B50/06

摘要： This invention relates to methods for the generation of polynucleotide seed libraries and the use of these libraries in generating novel mutants of recombinant proteins and, more particularly, for generating focused libraries of recombinant human antibodies and screening for their affinity binding with target antigens.

公开(公告)号：EP2126087A1

公开(公告)日：2009-12-02

申请号：EP08725984.2

申请日：2008-02-20

申请人： Anaptysbio, Inc.

发明人： HORLICK, Robert, A. ,  CUBITT, Andrew, B. ,  BOWERS, Peter, M.

IPC分类号： C12N15/13

CPC分类号： C07K16/461 ,  C07K16/00 ,  C07K16/22 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/565 ,  C07K2317/92 ,  C40B50/06

摘要： This invention relates to methods for the generation of polynucleotide seed libraries and the use of these libraries in generating novel mutants of recombinant proteins and, more particularly, for generating focused libraries of recombinant human antibodies and screening for their affinity binding with target antigens.

公开(公告)号：EP4188441A1

公开(公告)日：2023-06-07

申请号：EP21762854.4

申请日：2021-07-30

申请人： AnaptysBio, Inc.

发明人： PALLER, Amy ,  GUTTMAN, Emma ,  KHANSKAYA, Irina ,  KALAPANDA, Rupal ,  LONDEI, Marco

IPC分类号： A61K39/395 ,  A61P17/00 ,  A61P17/10 ,  C07K16/28

公开(公告)号：EP3980460A2

公开(公告)日：2022-04-13

申请号：EP20750003.4

申请日：2020-06-04

申请人： AnaptysBio, Inc.

发明人： KEHRY, Marilyn ,  PARMLEY, Stephen ,  MORSE, Robert P. ,  GOLD, Gregory N. ,  FISHER, Janean ,  DAHL, Martin Edward ,  MARINO, Margaret Habash ,  KALAPANDA, Rupal

IPC分类号： C07K16/28 ,  A61P37/06

公开(公告)号：EP3535586A2

公开(公告)日：2019-09-11

申请号：EP17867255.6

申请日：2017-11-01

申请人： AnaptysBio, Inc. ,  Tesaro Inc.

发明人： KING, David J. ,  KEHRY, Marilyn ,  GHOSH, Srimoyee ,  HUANG, Baochuan

IPC分类号： G01N33/574 ,  C07K16/28 ,  A61K39/395 ,  C07K16/30

公开(公告)号：EP3253798A4

公开(公告)日：2018-07-25

申请号：EP16747220

申请日：2016-02-03

申请人： ANAPTYSBIO INC

发明人： JUN HELEN TONI ,  KEHRY MARILYN ,  BOWERS PETER ,  KING DAVID J

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P31/00 ,  A61P35/00

CPC分类号： C07K16/2803 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  A61P31/00 ,  A61P35/00 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/524 ,  C07K2317/70 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30 ,  C07K2319/32 ,  Y02A50/386

摘要： The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a protein encoded by the Lymphocyte Activation Gene-3 (LAG-3). The invention provides a LAG-3-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the LAG-3-binding agent to treat a disorder or disease that is responsive to LAG-3 inhibition, such as cancer or an infectious disease.

公开(公告)号：EP3092253A4

公开(公告)日：2017-11-29

申请号：EP15735107

申请日：2015-01-09

申请人： ANAPTYSBIO INC

发明人： HORLICK ROBERT A ,  KING DAVID J ,  MCKNIGHT ANDREW JOHN

IPC分类号： C07K16/24

CPC分类号： C07K16/244 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

摘要： The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to interleukin-33 (IL-33). The invention provides an IL-33-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the IL-33-binding agent to treat a disorder in a mammal that is responsive to IL-33 inhibition.